Recent news coverage primarily relates to commodity prices and market conditions, with no direct recent news on Zeo ScientifiX’s core business activities. Past news includes insider share purchases and collaboration announcements.

• Cocoa prices settled higher due to Ivory Coast harvest delays [N1].
• Sugar prices were boosted by rains in Brazil, affecting cane crushing [N2][N4].
• Stock markets showed mixed performance influenced by lower crude prices and chipmaker weakness [N3][N7].
• Wheat prices slipped lower amid slow exports [N5].
• L3Harris Technologies and Divergent signed a teaming agreement, unrelated to Zeo ScientifiX [N6].
• Corn prices gained as crop ratings improved [N8].
• An insider purchased 5,000 shares of Zeo ScientifiX in February 2025 [N/A].
• Zeo ScientifiX announced collaboration on an innovative hair loss solution in early 2026 [N/A].

The company’s PPX™ service platform has demonstrated revenue growth and improved gross margins, indicating potential for expanding a higher-margin business segment. Continued sales and marketing efforts, including increased sales representatives and industry engagement, support this growth. The company’s ability to raise capital through private offerings provides working capital to support operations and development. Collaborations on innovative solutions, such as hair loss treatments, may diversify future revenue streams and enhance product offerings.

Zeo ScientifiX faces challenges including net losses and increased general and administrative expenses, particularly stock-based compensation costs. Competition in the biologic product market has led to decreased revenues in that segment. The company’s trading market is limited and sporadic, which may impact liquidity and investor access. Reliance on equity and debt financing to fund operations introduces risks related to capital availability and dilution. The company’s current liquidity ratios indicate tight working capital, which may constrain operational flexibility.

Zeo ScientifiX’s moat appears to be linked to its proprietary PPX™ service platform and its portfolio of allogenic aesthetic biologic products. The company faces competitive pressures in the biologic product market, which has impacted revenues. The PPX™ platform has shown growth and contributes a higher margin revenue stream. However, the company’s limited trading liquidity and reliance on external financing may constrain its competitive positioning. The absence of dividend payments and ongoing net losses suggest the company is still in a growth and investment phase rather than generating sustained profitability.

• Limited Market Liquidity: The company’s common stock trades on the OTCQB with limited and sporadic activity, which may affect the ability of shareholders to buy or sell shares efficiently [S1].
• Ongoing Net Losses: Zeo ScientifiX has reported net losses, including a $5.07 million loss for the fiscal year ended October 31, 2025, which may impact its financial stability and ability to fund operations without external financing [S1][S2].
• Competitive Pressure: Increased competition in the allogenic aesthetic biologic product market has led to decreased revenues in that segment, posing risks to revenue diversification and growth [S1].
• Dependence on External Financing: The company relies on sales of debt and equity securities to fund operations, which may lead to dilution and financing risk [S1].
• Tight Liquidity: As of June 30, 2026, the current ratio is 1.02 and cash ratio is 0.42, indicating limited liquidity buffer to cover short-term obligations [S2].

• Zeo ScientifiX, Inc. is publicly traded on the OTCQB market under the ticker ZEOX with limited and sporadic trading activity as of January 2026 [S1].
• As of January 28, 2026, the company had approximately 7.6 million shares outstanding and about 214 holders of record [S1].
• The company has never paid dividends and does not expect to pay dividends in the foreseeable future, intending to retain earnings for business growth [S1].
• For the fiscal year ended October 31, 2025, Zeo ScientifiX reported revenues of $5.2 million, a 12.5% increase from $4.6 million in 2024, driven primarily by growth in its PPX™ service platform [S1].
• The company’s revenue mix shifted with PPX™ service platform revenues increasing to 29.4% of total revenues in 2025 from 13.3% in 2024, while revenues from allogenic aesthetic biologic products decreased [S1].
• Gross profit for the year ended October 31, 2025 was $4.27 million, representing 82.0% of revenues, slightly higher than 81.7% in 2024 [S1].
• General and administrative expenses increased by 6.1% to $9.65 million in 2025, driven by higher stock-based compensation, lab costs, and professional fees, partially offset by lower commissions and marketing expenses [S1].
• The company reported a net loss of $5.07 million for the fiscal year ended October 31, 2025 [S1].
• Zeo ScientifiX has historically relied on sales of debt and equity securities to fund operations and completed a private offering in late 2025 raising $1.2 million for working capital [S1].
• As of June 30, 2026, the company reported $1.42 million in cash and equivalents, current assets of $3.49 million, and current liabilities of $3.42 million, resulting in a current ratio of 1.02 and a cash ratio of 0.42 [S2].
• For the fiscal year ended June 30, 2026, Zeo ScientifiX reported revenues of $5.87 million and a net loss of $5.07 million, with basic and diluted EPS of -$0.68 per share [S2].
• Recent news items do not directly reference Zeo ScientifiX’s business activities but cover commodity prices and market conditions [N1][N2][N3][N4][N5][N6][N7][N8].
• An insider purchase of 5,000 shares was reported in February 2025 [N/A].
• The company has engaged in collaborations on innovative hair loss solutions as of early 2026 [N/A].